CIK 0001228627 · Non-accelerated filer<br>Smaller reporting company
Opus Genetics, Inc.
Sign in to watch- Ticker
- IRD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 113516358
- Phone
- (984) 884-6030
- Business address
- 8 DAVIS DRIVE, SUITE 220, DURHAM, NC, 27713
- Former names
- Ocuphire Pharma, Inc., REXAHN PHARMACEUTICALS, INC., CORPORATE ROAD SHOW DOT COM INC, FERRARO FRANK
- 4 Grant or award President acquired 332,800 shares (grant or award)
- 4 Shares withheld for taxes Chief Executive Officer gave up 37,050 shares (to pay taxes)
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Grant or award Director acquired 100,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Director acquired 41,143 shares (grant or award)
- 4 Grant or award Director acquired 41,143 shares (grant or award)
- 4 Grant or award Director acquired 41,143 shares (grant or award)
- 4 Grant or award Director acquired 41,143 shares (grant or award)
- 4 Grant or award Director acquired 41,143 shares (grant or award)
- 4 Grant or award Director acquired 41,143 shares (grant or award)
- 4 Open-market buy Chief Scientific & Dev. Ofc. bought 3,500 shares at $1.77 ($6,178)
- 4 Open-market buy Chief Executive Officer bought 5,000 shares at $1.75 ($8,773)
- 4 Grant or award Director acquired 32,000 shares (grant or award)
- 4 Open-market buy Chief Operating Officer bought 2,000 shares at $2.05 ($4,100)
- 4 Open-market buy Chief Financial Officer bought 10,000 shares at $2.10 ($21,000)
- 4 Open-market buy Chief Executive Officer bought 25,000 shares at $1.96 ($49,050)
Page 5 of 21 · 403 filings